Our work also demonstrates that targeting eIF2-α phosphorylation represents a novel pharmacological option to interfere with endotoxemia both by reducing liver damage and altering TLR4-dependent cytokine release. This evidence concerns the gene EIF2A and serum lipopolysaccharide activity.